期刊文献+

HPLC-MS/MS法测定人血浆中尼古丁浓度 被引量:2

HPLC-MS/MS method for the determination of nicotine in human plasma
下载PDF
导出
摘要 目的建立简单、快速且灵敏的液质联用法检测人血浆中尼古丁的浓度。方法 血浆样品经二氯甲烷萃取后,采用Thermo Hypurity CN柱(2.1mm×150mm,5μm)分离,以乙腈-20mmol.L-1甲酸铵(50∶50,v/v)为流动相,流速为0.30mL·min-1。采用电喷雾离子源(ESI源)正离子多反应监测(MRM)扫描分析,尼古丁和d-4-尼古丁的离子选择通道分别为:m/z163→130和m/z 167→133.9。结果尼古丁的线性范围为0.597~76.48ng·mL-1,最低检测浓度为0.597ng·mL-1,平均提取回收率为70.7%~86.8%,日内和日间变异均<15%。结论本方法简单、灵敏、快速、重现性好,适用于尼古丁的人体临床药物代谢动力学及生物等效性研究。 Objective To establish a simple, rapid and sensitive HPLC-MS/MS method to determine nicotine in human plasma. Methods The plasma samples were extraced with dichloromethane. The nicotine and internal standard were separated on a Thermo Hypurity CN column (2.1 minx 150 ram, 5 μm) with the mobile phase containing acetonitrile and 20 mmol · L^-1 ammonium (50 : 50, v/v) at 0.30 mL · min^-1. The electrospray ionization with positive mode and multiple reaction monitor (MRM) were used. The most intense [M-H]+ MRM transition for niciotine and d4 nicotine was m/z163→130 and m/z 167→133.9. Results The linear range of the calibration curves for nicotine was 0. 597- 76.48 ng · mL^-1. The method recovery was 70.7%-86.8%. The intra-day and inter-day RSD was less than 15%. Conclusion This method is simple, sensitive, rapid and reproducible. It is suitable for the pharmacokinetic studies of nicotine.
出处 《中南药学》 CAS 2011年第11期836-839,共4页 Central South Pharmacy
关键词 液相色谱-质谱联用 尼古丁 药物动力学 生物等效性 LC-MS/MS nicotine pharmacokinetics bioequivalence
  • 相关文献

参考文献13

  • 1黄琳,殷彤,董振香.戒烟新药尼古丁透皮贴剂的临床应用和评价[J].中国新药杂志,2009,18(20):1926-1929. 被引量:7
  • 2Xu Y, Wang CJ, Zhang XP, et al. Fast and selective extraction of nicotine from human plasma based on magnetic strong cation exchange resin followed by liquid chromatography-tandem mass spectrometry [J]. Anal Bioanal Chem, 2011, 400 (2): 517- 526.
  • 3Beyer J, Peters FT, Kraemer T, et al. Detection and validated quantification of toxic alkaloids in human blood plasma-comparison of LC-APCI-MS with LC-ESI-MS/MS [J]. J Mass Spectrom, 2007, 42 (5): 621-633.
  • 4Kim I, Huestis MA. A validated method for the determination of nicotine, eotinine, trans-3'-hydroxycotinine, and nicotine in human plasma using solid-phase extraction and liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry [J]. J Mass Spectrom, 2006, 41 (6): 815-821.
  • 5Shakleya DM, Huestis MA. Simultaneous and sensitive measurement of nicotine, cotinine, trans-3'-hydroxycotinine and nor cotinine in human plasma by liquid chromatography-tandem mass spectrometry [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2009, 877 (29) : 3537 3542.
  • 6Yue B, Kushnir MM, Urry FM, et al. Quantitation of nicotine, its metabolites, and other related alkaloids in urine, serum, and plasma using LC-MS-MS [J]. Methods Mol Biol, 2010, 603 (1): 389 398.
  • 7Miller EI, Norris HR, Rollins DE, et al. A novel validated procedure for the determination of nicotine, eight nicotine metabolites and two minor tobacco alkaloids in human plasma or urine by solid-phase extraction coupled with liquid chromatography electrospray ionization-tandem mass spectrometry [J]. J Chro matogr B, Analyt Technol Biomed Life Sci, 2010, 878 (9- 10): 725-737.
  • 8Angela M DeVeaugh-Geiss, Lilan H Chen, Mitchell L Kotler, et al. Pharmacokinetic comparison of two nicotine transdermal systems, a 21 rag/24 Hour Patch and a 25 mg/16-Hour Patch:A randomized, open-label, single-dose, two-way crossover study in adult smokers [J]. Clinical Therapeutics, 2010, 32 (6) : 1140-1148.
  • 9Taylor PJ, Fprresst KK, Landsberg PG, et al. The Measurement of nicotine in human plasma by high-performance liquid chromatography-electrospray-tandem mass spectrometry [ J ]. Ther Drug Monit, 2004, 26 (5): 563-568.
  • 10Schiitte-Borkovec K, Heppel CW, Heling AN, et al. Analysis of myosmine, cotinine and nicotine in human toenail, plasma and saliva [J]. Biomarkers, 2009, 14 (5): 278-284.

二级参考文献21

  • 1BENOWITZ NL, HANSSON A, JACOB P. Cardiovascular effects of nasal and transdermal nicotine and cigarette smoking[ J ]. Hypertension,2002,39 ( 6 ) : 1107 - 1112.
  • 2ZEVIN S, BENOWITZ NL. Drug interactions with tobacco smoking: an update [ J ]. Clin Pharmacokinet, 1999,36 (6) : 425 - 438.
  • 3ABELIN T, EHRSAM R, BRIMER-REICHERT A, et al. Effectiveness of a transdermal nicotine system in smoking cessation studies[ J]. Methods Find Exp Clin Pharmacol, 1989,11 (3): 205 -214.
  • 4FIORE MC,KENFORD SL,JORENBY DE,et al Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments[ J ]. Chest, 1994,105 (2) :524 - 533.
  • 5TZIVONI D, KEREN A, MEYLER S,et al. Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking [ J ]. Cardiovasc Drugs Ther, 1998,12(3) : 239 -244.
  • 6HAJEK P, WEST R, FOULDS J,et al. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray,attd an inhaler[.I]. Arch Intern Med, 1999,159 (17) : 2033 -2038.
  • 7HASFORD J, FAGERSTROM KO, HAUSTEIN KO. A naturalistic cohort study on effectiveness, safety and usage pattern of an overthe-counter nicotine patch. Cohort study on smoking cessation [ J ]. Eur J Clin Pharmacol,2003,59 (5 - 6) :443 - 447.
  • 8TRIP JM, MANESH RP, JEFFREY BW, et al. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes[ J ]. J Cardiol,2005,95 : 976 - 978.
  • 9YANG G, FAN L, TAN J,et al. Smoking in China : findings of the 1996 National Prevalence Survey [ J ]. JAMA, 1999,282 ( 13 ) : 1247 - 1253.
  • 10HOLDEN C. Tobacco epidemic in China' s future [ J ], Science, 2001,293 : 1761 - 1762.

共引文献6

同被引文献57

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部